combination treatment with mek and akt inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivomek和akt抑制剂联合治疗更有效比每种药物单独使用人类非小细胞肺癌在体外和体内.pdf
文本预览下载声明
Combination Treatment with MEK and AKT Inhibitors Is
More Effective than Each Drug Alone in Human Non-
Small Cell Lung Cancer In Vitro and In Vivo
1 1 1 2 3 3
Jieru Meng *, Bingbing Dai , Bingliang Fang , B. Nebiyou Bekele , William G. Bornmann , Duoli Sun ,
3 4 4 5 5
Zhenghong Peng , Roy S. Herbst , Vassiliki Papadimitrakopoulou , John D. Minna , Michael Peyton ,
Jack A. Roth1
1 Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas,
United States of America, 2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 3 Department of
Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 4 Department of Thoracic/Head Neck
Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 5 Hamon Center for Therapeutic Oncology Research,
and Simmons Cancer Center, The University of Texas Southwestern Medical Center at Dallas, Texas, United States of America
Abstract
AZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this
combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating
resistance of non-small cell lung cancer (NSCLC) to AZD6244. Thus we hypothesized that dual inhibition of both
downstream MEK and AKT pathways would induce synergis
显示全部